Xavier Becerra is reflecting on tenure as HHS secretary. He told Scripps News, "We're leaving this country is healthier and stronger."

U.S. Health and Human Services Secretary Xavier Becerra says “this is a big deal.” Drug companies oppose the program.

Drugs used to treat cancer, diabetes and other chronic conditions are among 15 picked for negotiations that could result in lower prices for patients, the Department of Health and Human Services confirmed Friday.

The talks on drugs including Novo Nordisk's Wegovy, GSK's Trelegy Ellipta, and Pfizer's Xtandi will set Medicare prices that go into effect in 2027.

The Centers for Medicare & Medicaid Services announced 15 new drugs it wants to lower the cost for, including popular, but expensive weight-loss drugs.

Ozempic and Wegovy, the blockbuster but costly GLP-1 drugs often used for weight loss, are among the 15 medications that will be subject to the next round of Medicare price negotiations, the Biden administration announced Friday.

The Biden administration released another list of prescriptions drugs that would be subject to price controls. The price controls for the selected drugs will become effective in 2027.

Xavier Becerra is reflecting on tenure as HHS secretary. He told Scripps News, "We're leaving this country healthier and stronger."

Medicare will negotiate drug prices for popular medications like Ozempic and Wegovy, aiming to save billions for taxpayers

The popular weight-loss drugs were added to Medicare’s list of prices negotiated directly between the government and drug manufacturers.

The Centers for Medicare and Medicaid Services (CMS) identified 15 drugs it has selected for price negotiations with drug companies, including Rybelsus, another drug that works to combat diabetes and can lead to weight loss; Trelegy Ellipta, which treats chronic obstructive pulmonary disease and asthma; and Xtandi, which treats prostate cancer.